Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY6 | O43306 | 1/20 | 0.77 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.77 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.77 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.77 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.77 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.77 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.77 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.77 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.77 |
| ▸ | PNMT | P11086 | 6/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30578817 | 1.00 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL30578821 | 1.00 | ADCY6 (0.77) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Hydrochloric Acid SCHEMBL3322965 | 0.98 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL3503361 | 0.98 | ADCY6 (0.74) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL5793449 | 0.87 | ADCY6 (1.00) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL21465735 | 0.86 | ADCY6 (0.57) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL21475687 | 0.86 | ADCY6 (0.57) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL26318706 | 0.86 | ADCY6 (0.57) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL3181183 | 0.86 | ADCY6 (0.57) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| Bromide SCHEMBL11167892 | 0.85 | ADCY6 (0.95) | ADCY6ADCY3ADCY9ADCY5ADCY8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270949-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | Case Western Reserve University (US) | 2018-01-24 | — | — | EP | claimed |
| WO-2016149222-A2 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-22 | — | — | WO | claimed |
| EP-2486404-A1 | METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY | Wisconsin Alumni Research Foundation (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044253-A1 | METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110081675-A1 | Metabolic Biomarkers Of Drug-Induced Cardiotoxicity | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | claimed |
| US-5317014-A | Analgesics, antiinflammatory agents, antagonist, antiallergens or gastrointestinal disorders | ADIR ET COMPAGNIE (FR) | 1994-05-31 | — | — | US | claimed |
| EP-0517589-A2 | Tachykinin derivatives, their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-12-09 | — | — | EP | claimed |
| US-12428428-B2 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| CN-118290500-B | New pyridine alkaloid compound in purslane, and extraction and separation method and application thereof | 辽宁中医药大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-119822992-A | New amide alkaloid compound in purslane, and extraction and separation method and application thereof | 辽宁中医药大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-3270949-B1 | INSULIN ANALOGUES CONTAINING A GLUCOSE-REGULATED CONFORMATIONAL SWITCH | UNIV CASE WESTERN RESERVE (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-118290500-A | New pyridine alkaloid compound in purslane, and extraction and separation method and application thereof | 辽宁中医药大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| EP-0680323-B1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE POULENC RORER SA (FR) | 1997-04-02 | — | — | EP | disclosed |
| EP-0680323-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS. | RHONE POULENC RORER SA (FR) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994016697-A1 | SYNERGISING ASSOCIATION HAVING AN ANTAGONIST EFFECT ON NK1 AND NK2 RECEPTORS | RHONE-POULENC RORER S.A. (FR) | 1994-08-04 | — | — | WO | disclosed |
| US-5317014-A | Analgesics, antiinflammatory agents, antagonist, antiallergens or gastrointestinal disorders | ADIR ET COMPAGNIE (FR) | 1994-05-31 | — | — | US | disclosed |
| EP-0517589-A2 | Tachykinin derivatives, their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-12-09 | — | — | EP | disclosed |
| EP-0485583-A1 | USE OF TETRAHYDROISOQUINOLINE DERIVATIVES FOR PREPARING ANTITUMORAL DRUGS. | ROUSSEL UCLAF (FR) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018604-A1 | USE OF TETRAHYDROISOQUINOLINE DERIVATIVES FOR PREPARING ANTITUMORAL DRUGS | ROUSSEL-UCLAF (FR) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428428-B2 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | CYP19A1, GPER1, HSD17B11 | ADCY6 3057/4885ADCY3 3695/4885ADCY9 4008/4885 |
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | IAPP, GPR119, INSR | ADCY6 884/4885ADCY3 1173/4885ADCY9 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.